6. Cegla J, et al. Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake. Diabetes. 2014 Nov;63(11):3711-20. 7. Sanyal AJ, Bedossa P, Fraessdorf M, et al. A Phase 2...
参考文献 1. Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906). Available at https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/obesity/phase-ii-clinical-trial-weight-loss...
[2] “Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease.” Boehringer Ingelheim. www.boehringer-ingelheim.com/phase-3-studies-survodutide-obesity-and-overweight. Accessed June 2024 [...
原文链接:Lai Wei, Samina Ajaz Hussain, Mandy Fraessdorf, et al. East Asian Sub-Analysis of a Phase 2 Trial of the Glucagon and GLP-1 Receptor Dual Agonist Survodutide in People with Metabolic Dysfunction-Associated S...
1.Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906). Available at https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/obesity/phase-ii-clinical-trial-weight-loss-results. ...
参考来源:‘Boehringer receives US FDA Breakthrough Therapy designation and initiates two phase 3 trials in MASH for survodutide. News release. October 8, 2024.’ 注:本文旨在介绍医药健康研究,不作任何用药依据,具体用药指引,请咨询主治医师。
The phase 3 study will advance the safety findings of survodutide reported in the phase 2 study to aid overweight and obesity.
参考来源:‘Boehringer receives US FDA Breakthrough Therapy designation and initiates two phase 3 trials in MASH for survodutide. News release. October 8, 2024.’注:本文旨在介绍医药健康研究,不作任何用药依据,具体用药指引,请咨询主治医师。 送TA礼物 1楼2024-10-15 11:35回复 ...
“We are excited that survodutide will shortly enter Phase III trials through the global SYNCHRONIZE program for people living with overweight or obesity,” said David Kendall, MD, Chief Medical Officer of Zealand Pharma. “With novel peptide therapeutics like survodutide, we are targeting key me...
Boehringer Ingelheim and Zealand Pharma A/S have announced the initiation of 3 phase 3 trials investigating survodutide (BI 456906) for those living withoverweight or obesity. Recruitment will open for the trials soon, according to a statement from Boehringer Ingelheim. ...